[go: up one dir, main page]

WO2008055254A3 - Formulations and methods for oral delivery of proteins - Google Patents

Formulations and methods for oral delivery of proteins Download PDF

Info

Publication number
WO2008055254A3
WO2008055254A3 PCT/US2007/083362 US2007083362W WO2008055254A3 WO 2008055254 A3 WO2008055254 A3 WO 2008055254A3 US 2007083362 W US2007083362 W US 2007083362W WO 2008055254 A3 WO2008055254 A3 WO 2008055254A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug
methods
subject
delivering
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/083362
Other languages
French (fr)
Other versions
WO2008055254A2 (en
Inventor
Daniel A Carr
Nicholas A Peppas
Mathilde C Boudes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2008055254A2 publication Critical patent/WO2008055254A2/en
Publication of WO2008055254A3 publication Critical patent/WO2008055254A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions for delivering a drug to a subject are provided, as well as associated methods of making and using such compositions. In certain embodiments, a composition is provided for delivering a drug to a subject, the composition comprising hydrogel matrix formed from a copolymer of an acrylic acid and an N-vinyl pyrrolidone, wherein the hydrogel matrix is at least partially crosslinked and a drug, wherein the drug is disposed within the hydrogel matrix. Methods of making a composition for delivering a drug to a subject, as well as methods of treating a subject by administering to the subject such compositions, are also provided. In certain embodiments, these hydrogel networks may respond to pH changes, which may comprise swelling at increased pH to release at least a portion of the drug from the hydrogel network.
PCT/US2007/083362 2006-11-01 2007-11-01 Formulations and methods for oral delivery of proteins Ceased WO2008055254A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86384706P 2006-11-01 2006-11-01
US60/863,847 2006-11-01

Publications (2)

Publication Number Publication Date
WO2008055254A2 WO2008055254A2 (en) 2008-05-08
WO2008055254A3 true WO2008055254A3 (en) 2008-12-11

Family

ID=39345097

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/083362 Ceased WO2008055254A2 (en) 2006-11-01 2007-11-01 Formulations and methods for oral delivery of proteins

Country Status (1)

Country Link
WO (1) WO2008055254A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8183479B2 (en) 2009-05-01 2012-05-22 General Electric Company Lock mounting device
WO2011091307A1 (en) * 2010-01-23 2011-07-28 University Of Connecticut Affinity hydrogels for controlled protein release
US10500256B2 (en) 2014-09-30 2019-12-10 Board Of Regents, The University Of Texas System Polymers for delivery of therapeutic proteins
US10265405B2 (en) 2014-11-18 2019-04-23 Board Of Regents, The University Of Texas System Polymers for delivery of factor VIII and/or factor IX
WO2016115234A1 (en) * 2015-01-14 2016-07-21 Board Of Regents, The University Of Texas System Hydrogels for delivery of therapeutic compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US5573943A (en) * 1990-08-02 1996-11-12 Saramane Pty. Ltd. Cloning and expression of a rhoptry associated protein of P. falciparum

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4177056A (en) * 1974-06-27 1979-12-04 Ciba-Geigy Corporation Water-insoluble hydrophilic copolymers used as carriers for medicaments and pesticides
US5573943A (en) * 1990-08-02 1996-11-12 Saramane Pty. Ltd. Cloning and expression of a rhoptry associated protein of P. falciparum

Also Published As

Publication number Publication date
WO2008055254A2 (en) 2008-05-08

Similar Documents

Publication Publication Date Title
WO2008036147A3 (en) Drug delivery with stimulus responsive biopolymers
EA200800161A1 (en) NEW PHARMACEUTICAL COMPOSITIONS WITH MODIFIED DELIVERY AND METHOD OF OBTAINING SUCH COMPOSITIONS
WO2006017852A3 (en) Pharmaceutical compositions for controlled release delivery of biologically active compounds
WO2008039218A3 (en) Inhibitors of bruton's tyrosine kinase
WO2007048219A3 (en) Sustained drug release composition
TNSN08365A1 (en) Sustained release pharmaceutical composition on the basis of release system comprising an acid-soluble polymer and a ph-dependent polymer
HRP20070432A2 (en) Gastroresistant pharmaceutical formulations containing rifaximin
MX2009005644A (en) Gel useful for the delivery of ophthalmic drugs.
EP2402323A3 (en) Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
WO2009109613A3 (en) 1-BENZYL-3-HYDROXYMETHYLINDAZOIιE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1, CX3CR1
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
EP3895699A3 (en) Pharmaceutical compositions comprising iron oxy-hydroxide
AU2001296865A1 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2009109616A8 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
MY157790A (en) Trazodone composition for once a day administration
WO2005055948A3 (en) Epha2, epha4 and lmw-ptp and methods of treatment of hyperproliferative cell disorders
WO2008063768A3 (en) Compositions and methods for treating metabolic diseases
WO2007100555A3 (en) Compositions containing lactoferrin, and methods of using same to promote growth of skin cells
WO2008055254A3 (en) Formulations and methods for oral delivery of proteins
WO2005009287A3 (en) Drug delivery to the inner ear and methods of using same
GEP20115348B (en) Pharmaceutical composition for treating burns (variants) and methods for the production thereof (variants)
WO2007054976A3 (en) Lipid based controlled release pharmaceutical composition
WO2008136034A3 (en) Ophthalmic compositions for the treatment of ocular hypertension and glaucoma
WO2007109648A8 (en) Compositions and methods for modulating store-operated calcium entry
WO2008035229A3 (en) Compositions and methods for ph targeted drug delivery

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868645

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07868645

Country of ref document: EP

Kind code of ref document: A2